WIDEN: A tool for medical image management in multicenter clinical trials

Background It has been proposed that in clinical trials in which the therapeutic strategy is driven by functional imaging, central review of the images should be done in real time. Purpose We report our experience with a new tool for image exchange and review, called Web-Based Imaging Diagnosis by Expert Network (WIDEN), which we implemented for the HD0607 prospective multicenter Italian clinical trial in which Hodgkin lymphoma treatment was adapted based on results of an interim positron emission tomography (PET) scan performed after the first two cycles of chemotherapy. Methods We used WIDEN for general management of the clinical trial, site imaging qualification, image exchange, workflow control, blinded independent central review, inter-observer variability assessment, consensus creation, audit, and statistical analysis. Results As of February 2013, the interim PET was available for 512 patients; upon central review, 103 of the scans were judged to be positive and 409 to be negative. The median scan uploading and downloading times were 1 min, 25 s and 1 min, 55 s, respectively; the average and median times for diagnosis exchange were 47 h, 53 min and 37 h, 43 min, respectively. The binary concordance between pairs of reviewers (Cohen’s kappa) ranged from 0.72 to 0.85. The 5-point scale concordance among all reviewers (Krippendorf’s alpha) was 0.77. Conclusions WIDEN proved to be an effective tool for medical imaging exchange and online review. Data security, simplicity, feasibility, and prompt scan review were demonstrated. Central reviews were completed promptly.

[1]  Paul G Nagy,et al.  Cloud computing in medical imaging. , 2013, Medical physics.

[2]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[4]  J. Radford,et al.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  B. Freidlin,et al.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[8]  A. Rossi,et al.  Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.

[9]  W. D. Bidgood,et al.  Introduction to the ACR-NEMA DICOM standard. , 1992, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[11]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[12]  L. Mortelmans,et al.  FDG-PET: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Paul,et al.  The Internet and Clinical Trials: Background, Online Resources, Examples and Issues , 2005, Journal of medical Internet research.

[15]  M. Heldmann,et al.  Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[17]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[18]  T. Nihashi,et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Klaus Krippendorff,et al.  Answering the Call for a Standard Reliability Measure for Coding Data , 2007 .

[20]  J. Raemaekers,et al.  Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Cheson,et al.  Role of positron emission tomography in lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[23]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[24]  Martin Hutchings,et al.  PET/CT for Therapy Response Assessment in Lymphoma , 2009, Journal of Nuclear Medicine.

[25]  P. Marsden,et al.  Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Stephane Chauvie,et al.  International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.

[27]  D. Blockmans (18F)FLUORO-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH FEVER OF UNKNOWN ORIGIN , 2004, Acta clinica Belgica.

[28]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[29]  Alan Britten,et al.  Routine quality control recommendations for nuclear medicine instrumentation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.